Serving 500+ biopharmaceutical companies globally:
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
Serving 500+ biopharmaceutical companies globally:
Generated: September 25, 2017
| Title: | Osmotic continuous dispensing oral delivery system containing a pharmaceutically acceptable active agent having a improved core membrane adhesion properties |
| Abstract: | An osmotic dispensing delivery system suitable for oral administration, containing a pharmaceutically acceptable active agent for the controlled continuous release of about 50 to about 90 percent by weight of said active agent into the gastrointestinal tract at a rate of about 5 to about 12 percent by weight of said agent per hour consisting essentially of: (a) a shaped solid core containing an osmotically active composition comprising an effective amount of a pharmaceutically acceptable active agent, alone or in combination with a pharmaceutically acceptable binder, an osmotically active driving agent, or tabletting lubricant, or mixtures thereof; (b) said core being substantially evenly coated with a discrete layer of a water-soluble, or water-dispersible, and water permeable substantially non-osmotically active solid polymeric binder, said binder layer being present in an amount between about 0.3 percent and about 10 percent of the weight of the core; (c) a semi-permeable shaped wall member impermeable to said active composition and permeable to gastrointestinal fluid, surrounding and adhesively bonded to the binding layer; and (d) at least one passageway in the wall, for dispensing the active agent, in communication with said core and the external environment. |
| Inventor(s): | Shah; Shailesh B. (Union, NJ), Koparkar; Arun D. (Westfield, NJ) |
| Assignee: | Ciba-Geigy Corporation (Ardsley, NY) |
| Application Number: | 07/185,564 |
|
Patent Claim Types: see list of patent claims | Delivery; Composition; Dosage form; |
| Country | Document Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Germany | 58901373 | ► Subscribe | |||||||||||||
| Denmark | 196189 | ► Subscribe | |||||||||||||
| Denmark | 175232 | ► Subscribe | |||||||||||||
| European Patent Office | 0339506 | ► Subscribe | |||||||||||||
| Spain | 2031302 | ► Subscribe | |||||||||||||
| Finland | 891921 | ► Subscribe | |||||||||||||
| Finland | 90203 | ► Subscribe | |||||||||||||
| Greece | 3005399 | ► Subscribe | |||||||||||||
| Hungary | T50625 | ► Subscribe | |||||||||||||
| Hungary | 201469 | ► Subscribe | |||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws,
it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
Serving 500+ biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Follow DrugPatentWatch:
Join the 22,767 others who get our Drug Patent Expiration Alerts:
